Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSelmaj, Krzysztof W.
dc.contributor.authorCohen, Jeffrey A
dc.contributor.authorComi, Giancarlo
dc.contributor.authorArnold, Douglas L
dc.contributor.authorSteinman, Lawrence
dc.contributor.authorMontalban Gairín, Xavier
dc.contributor.authorBar-Or, Amit
dc.date.accessioned2022-02-24T16:27:50Z
dc.date.available2022-02-24T16:27:50Z
dc.date.issued2021-06
dc.identifier.citationSelmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, et al. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Mult Scler Relat Disord. 2021 Jun;51:102844.
dc.identifier.issn2211-0348
dc.identifier.urihttps://hdl.handle.net/11351/7079
dc.descriptionEsdeveniments adversos; Esclerosi múltiple; Ozanimod
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesMultiple Sclerosis and Related Disorders;51
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshMultiple Sclerosis, Relapsing-Remitting
dc.subject.mesh/drug therapy
dc.subject.meshTreatment Outcome
dc.titleOzanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.msard.2021.102844
dc.subject.decsesclerosis múltiple recurrente-remitente
dc.subject.decs/farmacoterapia
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.msard.2021.102844
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Selmaj KW] Center for Neurology, 90-324 Łódź, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, 11-082 Olsztyn, Poland. [Cohen JA] Department of Neurology, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA. [Comi G] Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy. [Bar-Or A] Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. [Arnold DL] NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, Quebec, H3A 2B4, Canada. [Steinman L] Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California 94305, USA. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid33892317
dc.identifier.wos000689354300026
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple